adults lacked insurance coverage for GLP-1 medications, leaving many to bear substantial out-of-pocket costs (Long, 2024)
In the SUSTAIN 7 trial, participants using semaglutide achieved significant improvements in blood sugar control and weight loss compared to other diabetes medications
While many people have utilized Ozempic off-label for weight loss, it still hasn't been approved for this use by the Food and Drug Administration (FDA)
Dyslipidemia has been reported in 2080% of patients with NAFLD [20]
Diabetes treatment typically focuses on blood sugar control, while weight-loss treatment focuses on appetite, fullness, and eating behavior
Constipation and Diarrhea Solutions Gastrointestinal motility changes unpredictably during titration